Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in oesophageal cancer (OC): Results of a biomarker analysis of a phase III  trial of gefitinib versus placebo (TRANS-COG).


Session type:

Russell Petty1,14, Asa Dahle-Smith1,14, Zofia Miedzybrodzka1,14, Susan Dutton2, Graeme Murray1,14, David Stevenson14, Doreen Massie14, Aileen Osbourne14, Caroline Clark14, Was Mansoor5, Joyce Thompson6, Mark Harrison7, Anirban Chatterjee8, Stephen Falk4, Sean Elyan9, Angel Garcia-Alonso10, David Fyfe12, Ian Chau11, Corran Roberts2, David Ferry13,2
1University of Aberdeen, Aberdeen, UK,2University of Oxford, Oxford, UK,3New Cross Hospital, Wolverhampton, UK,4University Hospitals Bristol NHS Foundation Trust, Bristol, UK,5Christie Hospital, Manchester, UK,6Birmingham Heartlands Hospital, Brimingham, UK,7Mount Vernon Cancer Centre, London, UK,8Royal Shrewsbury Hospital, Shrewsbury, UK,9Cheltenham General Hospital, Cheltenham, UK,10North Wales Cancer Centre, Rhyl, UK,11Royal Marsden Hospital, London, UK,12University Hospitals of Morrecombe Bay, Barrow in Furness, UK,13Lilly UK, Windlesham, UK,14NHS Grampian, Aberdeen, UK



Cancer  Oesophagus Gefitinib(COG) trial randomised 450 patients(pts)  with advanced OC progressing   after chemotherapy to gefitinib(G) or placebo(P).  Improved disease control rates(DCR), patient reported outcomes, and progression free survival(PFS) were seen with G-indicative of rapid and durable responses that were observed in a subgroup.  We hypothesised that  EGFR CNG in OCs would identify the subgroup  responsive to G.